TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Suresh S Ramalingam et al.PubMed ↗Publisher ↗

No numbers read from the abstract.